BlackRock Institutional Trust’s Acceleron Pharma XLRN Stock Holding History

BlackRock Institutional Trust’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$19.7M	Buy	771,977 +14,337	+2%	+$454K	﹤0.01%	1979
2016 Q3	$27.4M	Buy	757,640 +26,834	+4%	+$889K	﹤0.01%	1662
2016 Q2	$24.8M	Buy	730,806 +84,161	+13%	+$2.74M	﹤0.01%	1703
2016 Q1	$17.1M	Buy	646,645 +90,965	+16%	+$2.65M	﹤0.01%	1922
2015 Q4	$27.1M	Buy	555,680 +92,970	+20%	+$3.35M	﹤0.01%	1638
2015 Q3	$11.5M	Buy	462,710 +150,180	+48%	+$4.51M	﹤0.01%	2195
2015 Q2	$9.89M	Buy	312,530 +20,249	+7%	+$653K	﹤0.01%	2416
2015 Q1	$11.1M	Buy	292,281 +85,361	+41%	+$3.39M	﹤0.01%	2333
2014 Q4	$8.06M	Buy	206,920 +36,524	+21%	+$1.27M	﹤0.01%	2493
2014 Q3	$5.15M	Sell	170,396 -11,725	-6%	-$330K	﹤0.01%	2680
2014 Q2	$6.19M	Buy	182,121 +101,121	+125%	+$3.38M	﹤0.01%	2676
2014 Q1	$2.79M	Sell	81,000 -79,336	-49%	-$3.58M	﹤0.01%	3025
2013 Q4	$6.35M	Buy	+160,336	New	+$3.87M	﹤0.01%	2676

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BlackRock Institutional Trust's XLRN Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Acceleron Pharma (XLRN) stake by 1.9% in Q4 2016, buying an estimated $454K and bringing the position to 771,977 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1979.

BlackRock Institutional Trust first reported a position in XLRN in Q4 2013 and has held it in 13 quarters since. The position peaked at $27.4M in Q3 2016. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

BlackRock Institutional Trust held 771,977 shares of Acceleron Pharma worth $19.7M as of Q4 2016.
BlackRock Institutional Trust bought 14,337 Acceleron Pharma shares in Q4 2016, an estimated $454K.
Acceleron Pharma made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1979 holding.
BlackRock Institutional Trust first reported a position in Acceleron Pharma in Q4 2013 and has held it in 13 quarters since.
BlackRock Institutional Trust's Acceleron Pharma position peaked at $27.4M in Q3 2016.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.